The company's science program is quite well thought of though, with J&J's Janssen unit also signing a biobucks deal a few years ago with the entity. Here is that bit of news from FierceBiotech, this morning:
. . .Details remain vague, with Mestag providing Merck with options to acquire licenses to develop and commercialize therapies against a “prespecified number of potential targets.” The exact upfront payment the British biotech will receive hasn’t been disclosed, either, but the company did say that combined with access fees, option fees and “downstream payments,” the total value of the deal could reach $1.9 billion.
Fibroblasts are a type of connective tissue cell that have long been studied in the areas of wound healing and fibrosis, or scarring, but were traditionally considered bit players when it came to tumors and inflammation. More recently, researchers have started to understand that fibroblasts play not just a supporting role but a central one in inflammation. . . .
Merck also posted some nice head and neck cancer results for Keytruda today -- but those are also immaterial, since so many oncologists are already using it in these and other cancers. Now you know. Onward!
नमस्ते
No comments:
Post a Comment